As shown in Fig. 8C, CDKN2C expression was positively associated with TMB in LGG, UCS, GBM, and KICH (Spearman ρ > 0.3) and negatively associated with TMB in THYM (Spearman ρ = –0.66). Here, CDKN2C is linked to glioblastoma.